tbuckley/cabot-search huggingface dataset:
EPIG-10ABERRANT EPIGENOME IN GLIOBLASTOMA MULTIFORME
Authors: Annie Lin, Mitchel Berger
Journal: Neuro-Oncology (2015)

The fact that epigenetic alterations collaborate with genetic mutations to drive the evolution of cancer towards malignancy prompted us to dissect the aberrant epigenome with focus on post-translational modifications in glioblastoma multiforme (GBM). We initially utilized qualitative and quantitative proteome by Tandem Mass Tagging Orbitrap-Elite spectrometry and identified differential histone modification patterns in four distinct types of MRI-characterized GBM compared to control brain regions. We found that trimethylation on histone 3 lysine 4 (H3K4me3) and lysine 27 (H3K27me3), as well as acetylation on histone 3 lysine 9 (H3K9ac), lysine 27 (H3K27ac), and lysine 36 (H3K36ac) are altered in GBM. As these histone modifications are known to be either chromatin active or repressive marks, we carried out chromatin immunoprecipitation and deep-sequence (ChIP-Seq) to delineate differential enrichment of GBM genome by these histone modifications, and in parallel use RNA-Seq for gene expression profile of GBM. Through integrated analyses of ChIP-Seq and RNA-Seq, we found that changes in histone modification lead to very widespread effect on gene expression including cell cycle, cell death, mitochondrial metabolism, as well as PI3K and mTOR signaling pathways. Our studies highlight potential candidates for therapeutic targets of GBM. In addition, our proteomic analysis showed that neural stem and progenitor cell markers are highly expressed in GBM, suggesting that heterogeneous population of GBM share features with non-neoplastic stem cells. How changes in chromatin status could transform the normal stem cell toward cancer-initiating cells in GBM remain to be determined. Our future study will utilize single-cell RNA-Seq and proteome to thoroughly dissect the mechanism of cancerous initiation of GBM at single cell level. Emerging findings will diversify the approaches to cancer control and care by providing potential biomarkers for cancer diagnosis and prognosis.
The innovative serum protein N-glycans analysis predicts the extent of hepatic fibrosis in patients with nonalcoholic fatty liver disease
Authors: H Schmilovitz-Weiss, Cuiying Chen, Roland Contreras, O Pappo, M Halpern, J Sulkes, M Braun, M Cohen, N Barak, R Tur-Kaspa, Z Ben-Ari
Journal: Hepatology (2006)
Antimanic effects of verapamil
Authors: A J Giannini, W L Houser, R H Loiselle, M C Giannini, W A Price
Journal: American Journal of Psychiatry (1984)

When the authors compared the antimanic effects of verapamil, lithium carbonate, and placebo, no differences were seen between lithium and verapamil and both were more effective than placebo in reducing symptoms. No major side effects emerged during the study.
Catheter-Related Thrombosis: Risks, Diagnosis, and Management
Authors: Michael L. Linenberger
Journal: Journal of the National Comprehensive Cancer Network (2006)

Symptomatic thromboembolic complications of central venous catheters (CVCs) occur in 5% or less of general oncology patients. Asymptomatic CVC-related thrombi are more common, but their clinical significance is unclear. Thrombotic risk may be increased by primary thrombophilic disorders, especially the factor V G1691A (Leiden) mutation, thrombogenic catheter material, larger catheter diameter and greater number of lumens, catheter tip malposition, left-sided placement, percutaneous or multiple insertion attempts, a previous CVC or preexisting venous obstruction, prothrombotic therapeutic agents, catheter-associated infections, and fibrinous catheter lumen occlusion. Three recent randomized, prospective, placebo-controlled trials observed no benefit of routine low-dose warfarin or low-molecular-weight heparin in preventing catheter-associated thrombosis. Nevertheless, thromboprophylaxis may be appropriate and safe for selected high-risk patients. Duplex ultrasound can accurately detect CVC-related thrombi involving the jugular, axillary, distal subclavian, and arm veins. Contrast venographic imaging is required for indeterminate duplex findings and to evaluate the deep central veins and pulmonary arteries. Therapeutic anticoagulation, with or without catheter removal, is indicated for patients with acute deep vein thrombosis (DVT) or pulmonary embolism who have no contraindications. Catheter removal alone, with close follow-up, may be sufficient when bleeding risk precludes safe anticoagulation. Approaches to managing catheter-associated thrombosis, including the use of thrombolytic agents, are guided by limited published experience and extrapolation from practices used for lower-extremity DVT. Prospective, randomized, controlled trials are needed to identify the safest and most effective anticoagulant agents, treatment durations, and alternative venous access strategies for cancer patients who develop catheter-associated thrombosis.
Magnetization-tagged MRI is a simple method for predicting liver fibrosis
Authors: Kyung-Eun Kim, Mi-Suk Park, Sohae Chung, Chansik An, Leon Axel, Rakhmonova Gulbahor Ergashovna
Journal: Clinical and Molecular Hepatology (2016)

To assess the usefulness of magnetization-tagged magnetic resonance imaging (MRI) in quantifying cardiac-induced liver motion and deformation in order to predict liver fibrosis. This retrospective study included 85 patients who underwent liver MRI including magnetization-tagged sequences from April 2010 to August 2010. Tagged images were acquired in three coronal and three sagittal planes encompassing both the liver and heart. A Gabor filter bank was used to measure the maximum value of displacement (MaxDisp) and the maximum and minimum values of principal strains (MaxP1 and MinP2, respectively). Patients were divided into three groups (no fibrosis, mild-to-moderate fibrosis, and significant fibrosis) based on their aspartate-aminotransferase-to-platelet ratio index (APRI) score. Group comparisons were made using ANOVA tests. The patients were divided into three groups according to APRI scores: no fibrosis (≤ 0.5; n=41), moderate fibrosis (0.5-1.5; n=23), and significant fibrosis (>1.5; n=21). The values of MaxDisp were 2.9 ± 0.9 (mean ± SD), 2.3 ± 0.7, and 2.1 ± 0.6 in the no fibrosis, moderate fibrosis, and significant fibrosis groups, respectively (P<0.001); the corresponding values of MaxP1 were 0.05 ± 0.2, 0.04 ± 0.02, and 0.03 ± 0.01, respectively (P=0.002), while those of MinP2 were -0.07 ± 0.02, -0.05 ± 0.02, and -0.04 ± 0.01, respectively (P<0.001). Tagge d MRI to quantify cardiac-induced liver motion can be easily incorporated in routine liver MRI and may represent a helpful complementary tool in the diagnosis of early liver fibrosis.
Coronary Microvascular Dysfunction as a Mechanism of Angina in Severe AS
Authors: Jong-Hwa Ahn, Sung Mok Kim, Sung-Ji Park, Dong Seop Jeong, Min-Ah Woo, Sin-Ho Jung, Sang-Chol Lee, Seung Woo Park, Yeon Hyeon Choe, Pyo Won Park, Jae K. Oh
Journal: Journal of the American College of Cardiology (2016)
Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena
Authors: Murray Epstein
Journal: Kidney International Supplements (2016)

Recent studies have reported a large gap between the forceful and assertive recommendations in the guidelines and real-world practice in the use of renin-angiotensin-aldosterone inhibitors (RAASi) therapies. A comprehensive, retrospective analysis of a large database of electronic medical records (>7 million patients) was undertaken to evaluate 3 pivotal concerns: (i) whether RAASi are being prescribed according to treatment guidelines, (ii) what happens to RAASi prescriptions after hyperkalemia events, and (iii) what the clinical outcomes are in patients whose RAASi are discontinued or who are prescribed at doses lower than the guidelines recommend. The results indicate that a substantial gap exists between guideline recommendations and real-world prescribing patterns for RAASi. Among patients with cardiorenal comorbidities for which RAASi are recommended by the guidelines, more than one-half were prescribed lower-than-recommended doses, and approximately 14% to 16% discontinued RAASi therapy. RAASi prescribing patterns may be altered by the development of hyperkalemia. Moderate-to-severe hyperkalemia events were followed by down-titration or discontinuation of RAASi therapy in nearly one-half of all patients on maximal dose and by discontinuation in nearly one-third of patients on submaximal dose. This analysis highlights the challenge behind RAASi prescribing decisions, balancing the risk of provoking hyperkalemia with the benefits to reducing cardiorenal morbidity and mortality. Patients who are known to derive the greatest benefit from these drugs (chronic kidney disease patients with concomitant diabetes mellitus or heart failure) are the same patients who are at highest risk of developing hyperkalemia. These observations constitute a "call to action" to develop newer treatment modalities to lower serum potassium and to achieve and sustain normokalemia long-term.
Detection of Virus-Specific RNA in Herpes Simplex Virus Type 1-Transformed Hamster Cell Lines&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: Y Eizuru, R W Hyman, J W Kreider, F Rapp
Journal: JNCI Journal of the National Cancer Institute (1983)

In situ hybridization experiments with the use of recombinant herpes simplex virus type 1 DNA as probes have detected virus-specific RNA in herpes simplex virus type 1-transformed Syrian hamster cell lines. The relatively most abundant virus transcripts hybridized to the herpes simplex virus type 1 EcoRI-F fragment at map position 0.32-0.42.
Abstract 17738: Elastic Fibril Protein Fibulin-2 Expression is Increased in Fibro Elastic Deficiency Compared to Barlow's Disease- Implication in Disease Progression
Authors: Meerarani Purushothaman, Purushothaman K-Raman, Ioannis Karakikes, David H Adams, Federico Milla, Annapoorna Kini, Samin K Sharma, Valentin Fuster, Pedro R Moreno
Journal: Circulation (2012)
<i>Pseudomonas</i> infection and mucociliary and absorptive clearance in the cystic fibrosis lung
Authors: Landon W. Locke, Michael M. Myerburg, Daniel J. Weiner, Matthew R. Markovetz, Robert S. Parker, Ashok Muthukrishnan, Lawrence Weber, Michael R. Czachowski, Ryan T. Lacy, Joseph M. Pilewski, Timothy E. Corcoran
Journal: European Respiratory Journal (2016)

Airway surface liquid hyperabsorption and mucus accumulation are key elements of cystic fibrosis lung disease that can be assessed in vivo using functional imaging methods. In this study we evaluated experimental factors affecting measurements of mucociliary clearance (MCC) and small-molecule absorption (ABS) and patient factors associated with abnormal absorption and mucus clearance. Our imaging technique utilises two radiopharmaceutical probes delivered by inhalation. Measurement repeatability was assessed in 10 adult cystic fibrosis subjects. Experimental factors were assessed in 29 adult and paediatric cystic fibrosis subjects (51 scans). Patient factors were assessed in a subgroup with optimal aerosol deposition (37 scans; 24 subjects). Paediatric subjects (n=9) underwent initial and 2-year follow-up scans. Control subjects from a previously reported study are included for comparison. High rates of central aerosol deposition influenced measurements of ABS and, to a lesser extent, MCC. Depressed MCC in cystic fibrosis was only detectable in subjects with previous Pseudomonas aeruginosa infection. Cystic fibrosis subjects without P. aeruginosa had similar MCC to control subjects. Cystic fibrosis subjects had consistently higher ABS rates. We conclude that the primary experimental factor affecting MCC/ABS measurements is central deposition percentage. Depressed MCC in cystic fibrosis is associated with P. aeruginosa infection. ABS is consistently increased in cystic fibrosis.
mTORC1-Dependent Metabolic Reprogramming Underlies Escape from Glycolysis Addiction in Cancer Cells
Authors: Raju V. Pusapati, Anneleen Daemen, Catherine Wilson, Wendy Sandoval, Min Gao, Benjamin Haley, Andreas R. Baudy, Georgia Hatzivassiliou, Marie Evangelista, Jeff Settleman
Journal: Cancer Cell (2016)
Nephroblastoma in the Rat: Histology of a Spontaneous Tumor, Identity With Respect to Renal Mesenchymal Neoplasms, and a Review of Previously Recorded Cases2
Authors: Gordon C. Hard, P. Grasso
Journal: JNCI Journal of the National Cancer Institute (1976)

Journal Article Nephroblastoma in the Rat: Histology of a Spontaneous Tumor, Identity With Respect to Renal Mesenchymal Neoplasms, and a Review of Previously Recorded Cases Get access Gordon C. Hard, Gordon C. Hard Search for other works by this author on: Oxford Academic PubMed Google Scholar P. Grasso P. Grasso Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 57, Issue 2, August 1976, Pages 323–329, https://doi.org/10.1093/jnci/57.2.323 Published: 01 August 1976 Article history Received: 06 October 1975 Accepted: 23 January 1976 Published: 01 August 1976
Melaena Caused by Small Bowel Metastases of Colorectal Cancer in Presence of Anastomotic Recurrence
Authors: B P Waxman, P T Gill, I L Rosenberg
Journal: Journal of the Royal Society of Medicine (1985)

Discussion Secondary tumours of the bladder are rare and are usually from direct invasion from adjacent organs. In an extensive retrospective study, Ganem & Batal (1956) reported on 80 cases of secondary tumours of the urinary bladder, of which 25 were from a primary in the stomach, 18 from melanoma and 6 from bronchial carcinomas of unspecified type. There have been no recent reports in the literature of small cell carcinoma of the bronchus metastasizing to the bladder. However, there have been two recent reports of small cell neuroendocrine tumours occurring in the bladder without any evidence of a primary bronchial neoplasm (Davis et al. 1983, Cramer et al. 1981). Two of the 4 patients had disseminated disease and chemotherapy for small cell bronchial tumours induced partial remissions. Our patient had too low a Karnofsky score to be considered suitable for intensive chemotherapy. However, in suitable patients with disseminated small cell carcinomatosis, modern chemotherapeutic regimens containing an alkylating agent with etoposide can induce complete remissions in up to 25% of cases (Sprio 1985). It is suggested that an oncological opinion be sought should the initial diagnosis be made by an urologist, so that effective chemoand radiotherapy can be started.
Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry
Authors: Chris Kay, Jennifer A Collins, Niels H Skotte, Amber L Southwell, Simon C Warby, Nicholas S Caron, Crystal N Doty, Betty Nguyen, Annamaria Griguoli, Colin J Ross, Ferdinando Squitieri, Michael R Hayden
Journal: Molecular Therapy (2015)

Huntington disease (HD) is a dominant neurodegenerative disorder caused by a CAG repeat expansion in the Huntingtin gene (HTT). Heterozygous polymorphisms in cis with the mutation allow for allele-specific suppression of the pathogenic HTT transcript as a therapeutic strategy. To prioritize target selection, precise heterozygosity estimates are needed across diverse HD patient populations. Here we present the first comprehensive investigation of all common target alleles across the HTT gene, using 738 reference haplotypes from the 1000 Genomes Project and 2364 haplotypes from HD patients and relatives in Canada, Sweden, France, and Italy. The most common HD haplotypes (A1, A2, and A3a) define mutually exclusive sets of polymorphisms for allele-specific therapy in the greatest number of patients. Across all four populations, a maximum of 80% are treatable using these three target haplotypes. We identify a novel deletion found exclusively on the A1 haplotype, enabling potent and selective silencing of mutant HTT in approximately 40% of the patients. Antisense oligonucleotides complementary to the deletion reduce mutant A1 HTT mRNA by 78% in patient cells while sparing wild-type HTT expression. By suppressing specific haplotypes on which expanded CAG occurs, we demonstrate a rational approach to the development of allele-specific therapy for a monogenic disorder. Huntington disease (HD) is a dominant neurodegenerative disorder caused by a CAG repeat expansion in the Huntingtin gene (HTT). Heterozygous polymorphisms in cis with the mutation allow for allele-specific suppression of the pathogenic HTT transcript as a therapeutic strategy. To prioritize target selection, precise heterozygosity estimates are needed across diverse HD patient populations. Here we present the first comprehensive investigation of all common target alleles across the HTT gene, using 738 reference haplotypes from the 1000 Genomes Project and 2364 haplotypes from HD patients and relatives in Canada, Sweden, France, and Italy. The most common HD haplotypes (A1, A2, and A3a) define mutually exclusive sets of polymorphisms for allele-specific therapy in the greatest number of patients. Across all four populations, a maximum of 80% are treatable using these three target haplotypes. We identify a novel deletion found exclusively on the A1 haplotype, enabling potent and selective silencing of mutant HTT in approximately 40% of the patients. Antisense oligonucleotides complementary to the deletion reduce mutant A1 HTT mRNA by 78% in patient cells while sparing wild-type HTT expression. By suppressing specific haplotypes on which expanded CAG occurs, we demonstrate a rational approach to the development of allele-specific therapy for a monogenic disorder.
Studies' assumptions are removed from clinical practice
Authors: I. Trimble, C. Derett
Journal: BMJ (1996)

Cost effectiveness of screening for and eradication of Helicobacter pylori in young patients with dyspepsia Analysis is easier with spreadsheets than decision trees EDITOR,-A H Briggs et al provide an interesting perspective on the problem of what best to do for people with dyspepsia.'Clarification would be
Psychiatric and medical diagnoses as risk factors for mortality in psychiatric patients: a case-control study
Authors: G Winokur, D W Black
Journal: American Journal of Psychiatry (1987)

On the basis of a case-control study, the authors conclude that former psychiatric inpatients are more likely than control subjects to die of both natural and unnatural causes within 2 years of discharge. Patients who committed suicide were more likely to have had a diagnosis of affective disorder (unipolar depression) or alcoholism. Those who died of natural causes were more likely to have been admitted with medical diagnoses; no specific psychiatric diagnoses were associated with these deaths. It is doubtful that medical illnesses caused psychiatric syndromes such as depression in these inpatients. Psychiatric and medical illnesses combined may increase a patient's likelihood of seeking psychiatric help and entering the hospital.
Severe Mitral Regurgitation in Hypovolemic Shock Masquerading as Mitral Valve Perforation
Authors: Colin T. Phillips, Michael C. Gavin, Eli V. Gelfand
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
p85α is an intrinsic regulator of human natural killer cell effector functions
Authors: Vassilios Lougaris, Ornella Patrizi, Manuela Baronio, Giovanna Tabellini, Giacomo Tampella, Gaetana Lanzi, Filippo Salvini, Antonino Trizzino, Silvia Parolini, Alessandro Plebani
Journal: Journal of Allergy and Clinical Immunology (2016)
Trends in Mortality From Ischemic Heart Disease and Cerebrovascular Disease in Europe
Authors: Adam Hartley, Dominic C. Marshall, Justin D. Salciccioli, Markus B. Sikkel, Mahiben Maruthappu, Joseph Shalhoub
Journal: Circulation (2016)

Background— Trends in cardiovascular mortality across Europe demonstrate significant geographical variation, and an understanding of these trends has a central role in global public health. Methods and Results— Ischemic heart disease and cerebrovascular disease age-standardized death rates (as per International Classification of Diseases , ninth and tenth revisions) were collated from the World Health Organization mortality database for member states of the European Union. Trends were characterized by using Joinpoint regression analysis. An overall trend for reduction in ischemic heart disease mortality was observed, most pronounced in Western Europe (&gt;60% for the Netherlands, United Kingdom, and Ireland) for both sexes from 1980 to 2009. Eastern European states, Romania, Croatia, and Slovakia, had modest mortality reductions. Most recently (2009), Lithuania had the highest mortality for males and females (318.1/100 000 and 166.1/100 000, respectively), followed by Latvia and Slovakia. France had the lowest mortality: 39.8/100 000 for males and 14.7/100 000 for females. Analysis of cerebrovascular disease mortality revealed that Austria had the largest reduction for both sexes (76.8% males, 76.5% females) from 1980 to 2009. The smallest improvement over this period was seen in Lithuania, Poland, and Cyprus (–5% to +20% approximately). France has the lowest present-day cerebrovascular disease mortality for both males and females (23.9/100 000 and 17.3/100 000, respectively). Conclusions— There is a growing disparity in cardiovascular mortality between Western and Eastern Europe, for which diverse explanations are discussed. The need for population-wide health promotion and primary prevention policies is emphasized.